CRISPR Therapeutics Stock News

There are many must-own stocks beyond the mega-caps that aren't household names but have solid potential going forward. These stocks are using megatrends and tailwinds and have solid upside catalysts

CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

ZUG, Switzerland and BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseas

For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let's get some of the bad stuff out of the way fir

CRISPR Therapeutics is in the process of launching its first medicine. It has plenty of cash, no debt, and manageable expenses.

The final trades of the day with CNBC's Melissa Lee and the Option Action traders.

-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A.

If you have a budget of around $1,000 and you'd like to buy some solid stocks to beat the market, I've got you covered! The stocks in this article total around ~$383 as of writing if you bought one of

CRISPR Therapeutics is finally at the cusp of profitability. Its pipeline has quite a few promising opportunities beyond the approved therapies.

Indexes are extending bull market gains, reaching new records. It's not too late to get in on the action -- history suggests this bull market could have much farther to go.

National Bank of Canada FI lessened its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 63.7% during the fourth quarter, according to the company in its most recent 13F filing wit

CRISPR develops cutting-edge therapies that could be transformative. The gene-editing specialist has launched its first approved treatment.

They say the best time to invest was 20 years ago. And indeed, that's not too long after the early 2000s recession bottomed out.

CRISPR reported rising losses on deeply lower revenue last week. The gene-editing biotech is, however, making progress on several therapies, and ready to bring its first treatment to market.

The healthcare sector has attractive stocks for any investment strategy. Pfizer has an impressive product pipeline and an attractive valuation as well.